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Epidemic influenza is associated with significant morbidity and mortality, particularly for the elderly and people at risk ([@ref1]). The European Center for Disease Control (ECDC) estimates that, about 40,000 people, each year, die prematurely due to influenza in the European Union. A large proportion of influenza-related deaths occur in individuals older than 65 years, especially among those with chronic underlying conditions ([@ref2], [@ref3]). The prevention of influenza represents an important Public Health intervention, involving Health Services every year in the implementation of the vaccination campaign ([@ref4]). The vaccine significantly reduces complications, hospitalization and mortality excess in those most at risk, as well as health care costs through the reduction of drug consumption, and the social costs associated with the flu epidemic ([@ref5]-[@ref13]).

The viral strains in influenza vaccines have to be evaluated and updated regularly because circulating influenza viruses continuously evolve. Annually, an advisory group of experts analyses influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS), and issues recommendations on the composition of the influenza vaccines for the following influenza season. These recommendations are used by the national vaccine regulatory agencies and the pharmaceutical companies to develop, produce and license influenza vaccines. Approximately 6-8 months are needed to produce vaccines ([@ref14]). Recommendations for the following influenza season are usually made in February in the Northern Hemisphere and in September in the Southern Hemisphere. According to the virological surveillance activity, in 2019, the formulation of the influenza vaccine for the Northern Hemisphere was postponed by about a month to allow a better definition of the A(H3N2) strain, genetically and antigenically different from the previous vaccine strain ([@ref15]).

In recent years the need for Public Health to carry out rigorous and repeated studies, to obtain solid estimates of vaccine effectiveness (VE) performed at mid-season "interim" and at the end season, has been highlighted ([@ref16]-[@ref21]). Vaccine effectiveness refers to the impact of a vaccine assessed using observational studies ([@ref22]). Since the 2008/2009 influenza season, in many European countries (8 to 12), including Italy, several studies have been conducted with the Test Negative design (TN) to assess this effectiveness ([@ref23]-[@ref30]). Starting from the 2014-2015 season, the Emilia-Romagna Region, with 5 other Italian Regions (Piedmont, Valle D'Aosta, Lombardy, Friuli Venezia Giulia and Puglia), was officially involved in the multicenter case-control observational study " I-Move "(Influenza Monitoring Vaccine Effectiveness in Europe) on field effectiveness of influenza vaccines, coordinated by the Istituto Superiore di Sanità (ISS) ([@ref31]).

During the 2018/2019 season, within the context of integrated virological and epidemiological surveillance coordinated by the ISS and conducted in Emi-lia-Romagna, at the Regional Reference Laboratory of Parma, a test-negative case-control design was established in order to produce seasonal influenza VE estimates, and interim VE estimates.

Methods {#sec1-2}
=======

During the 2018/2019 influenza season, 31 General Practitioners (GPs) and 18 Pediatricians (P) from the InfluNet network of Emilia-Romagna Region (Bologna, Ferrara, Forlì-Cesena, Modena, Parma, Piacenza and Reggio Emilia) performed nasal or throat swabs on not hospitalized infants, children and adults with ILI (Influenza-like illness). The Care Units of Piacenza, Parma and Reggio Emilia Hospitals performed nasal or throat swabs on patients admitted with influenza-like symptoms and/or severe acute respiratory diseases. According to operative InfluNet protocol ([@ref32]), for each sample, information on age, sex, vaccination status, presence/absence of chronic diseases, and Care Unit for hospitalized patients, were collected. For data analysis, the subjects were stratified into 4 age groups: 0-4 years, 5-14 years, 15-64 years and \>65 years. Laboratory diagnosis was undertaken by using one-step Real Time retro-transcription PCR assay (rRT-PCR), able to detect circulating influenza A and B viruses and subtypes. For rRT-PCR positive samples, influenza viruses were also isolated in MDCK or MDCK-SIAT1 cells (Madin-Darby Canine Kidney), specific for the growth of influenza viruses. Protocols and materials (kits, primers and probes) indicated by the CDC (Centers for Disease Control and Prevention) and WHO (World Health Organization) were used ([@ref33]). Further strain characterisation was performed by the Reference Laboratory Network of the Italian National Influenza Center (NIC) on a selected number of influenza virus isolates.

Under the TN design, subjects who seek medical care for ILI and tested positive for influenza virus infection were cases, subjects who seek medical care for ILI and tested negative for influenza virus infection were non case/control.

To estimate the VE, the season in study was divided in three periods, considering the peak epidemic period (peak: 5^th^ - 7^th^ week/2019), the previous weeks (pre-peak: 46^th^ week/2018 - 4^th^ week/2019) and the following weeks (post-peak: 8^th^ - 17^th^ week/2019) at the peak period. VE was estimated as (1- ORadj) x 100 with the relative confidence intervals of 95% (95% CI). In particular, were estimated: the seasonal influenza VE (overall) and the VE against subtype A (H1N1)pdm09 and subtype A(H3N2) (adjusted for epidemic period, age group and sex); the interim VE estimates in the three considered periods of the season (adjusted for age group and sex).

The results were summarized in frequency tables and analyzed with the X^2^ test with Yates continuity correction when necessary. A logistic regression model was used for the calculation of the adjusted VE for sex, age group and epidemic period. All statistical analyses were performed with SPSS 25.0 (IBM SPSS Inc., Chicago -- IL).
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=======

From November 2018 to April 2019, 2,230 specimens were analyzed. 1,674 samples (75.1%) came from hospital Care Units, in particular from the Medicine Unit (29.6%), Geriatrics and Long-term Care Units (27.1%) Emergency-Urgency Unit (12.2%), Pediatrics Unit (7.8%) and Intensive Care Unit (7%) ([Figure 1](#F1){ref-type="fig"}); 556 swabs (24.9%) came from GPs and P of the regional network. Overall, 704 samples were positive (31.6%); 48.6% of swabs performed by sentinel practitioners and 25.9% by hospital Care Units, were positive ([Table 1](#T1){ref-type="table"}).

![Number of swabs and specimens positive for influenza virus by hospital Care Unit](ACTA-90-21-g001){#F1}

###### 

Characteristics of patients in the 2018/19 influenza-season in Emilia Romagna-Region

  Characteristic                        Outpatients No. (%)   Inpatients No. (%)
  ------------------------------------- --------------------- --------------------
  **Overall**                           556 (24.9)            1674 (75.1)
  **Province**                                                
  Bologna                               41 (7.4)              \-
  Ferrara                               72 (13.0)             \-
  Forli-Cesena                          31 (5.6)              \-
  Modena                                52 (9.3)              \-
  Parma                                 284 (51.1)            1370 (81.8)
  Piacenza                              29 (5.2)              200 (11.9)
  Reggio Emilia                         47 (8.4)              104 (6.3)
  **Sex**                                                     
  Female                                245 (44.1)            872 (52.1)
  Male                                  311 (55.9)            802 (47.9)
  **Age group (years)**                                       
  0-4                                   194 (34.9)            85 (5.1)
  5-14                                  204 (36.7)            42 (2.5)
  15-64                                 144 (25.9)            484 (28.9)
  ≥65                                   14 (2.5)              1063 (63.5)
  **Vaccination Status**                                      
  Unvaccinated                          476 (85.7)            1048 (62.6)
  Vaccinated                            77 (13.8)             448 (26.8)
  Missing information                   3 (0.5)               178 (10.6)
  **Target group for vaccination**                            
  No                                    477 (85.8)            296 (17.7)
  Yes                                   79 (14.2)             1316 (78.6)
  Missing information                   0 (0)                 62 (3.7)
  **Influenza Laboratory Diagnosis**                          
  Positive                              270 (48.6)            434 (25.9)
  Negative                              286 (51.4)            1240 (74.1)
  **Influenza virus type or subtype**                         
  A(H3N2)                               152 (56.3)            252 (58.1)
  A(H1N1)pdm09                          115 (42.6)            175 (40.3)
  A unsubtyped                          3 (1.1)               6 (1.4)
  Influenza B                           0 (0)                 1 (0.2)

This influenza season was characterized by an initial period of low incidence, until the end of December 2018 and by an intensification of the viral activity at the beginning of the new year, with an incidence rate of 14 cases per 1000 person/years in the 5^th^ week. In 2018/2019 season, the trend of the epidemic showed a peak around the 6^th^ surveillance week. From a virological point of view, the season was characterized by the predominant circulation of influenza type A viruses (99.9%); of these, 57.4% belonged to subtype A(H3N2), 41.2% to subtype A(H1N1)pdm09 and the remaining 1.3% was not subtyped. Within type A, viruses of the two subtypes A(H3N2) and A(H1N1)pdm09 always co-circulated, although the A(H1N1)pdm09 strains were found to be prevalent in the first half of the epidemic season, and the A(H3N2) strains from the second half of February onwards. One virus type B, belonging to the B/Yamagata lineage, was isolated ([Figure 2](#F2){ref-type="fig"}). Subtype A(H3N2) circulated more than subtype A(H1N1)pdm09, both in outpatients (56.3% vs 42.6%) and in inpatients (58.1% vs 40.3%) ([Table 1](#T1){ref-type="table"}). Although the highest number of swabs was performed on subjects older than 65 years (48.3%), the highest number of positive samples was identified in pediatric ages, 5-14 years (55.3%) and 0-4 years (42.3%). While in the age group 0-4 years, the subtypes A(H3N2) and A(H1N1)pdm09 co-circulated (50% vs 50%), in the classes 5-14 and over 65 years, circulated mainly the A(H3N2) (67.6% vs 30.9% and 69.8% vs 29.4% respectively). Subtype A(H1N1)pdm09, on the other hand, circulated more frequently in the age group 15-64 years (58.5% vs 38.5%). 23.5% of the subjects was vaccinated; considering subjects belonging to the age group greater than 65 years and/or with chronic diseases, for whom vaccination is strongly recommended, 36.6% of these, was vaccinated. According to the indications of Italian Ministry of Health ([@ref34]), all vaccinated subjects were immunized with a quadrivalent or adjuvated (trivalent) vaccine; 29.1% of these, contracted influenza, and in particular 74.5% were positive for subtype A(H3N2) and 24.8% for subtype A(H1N1)pdm09. The overall VE was -5% (95% CI -33% - 18%) with a decreasing trend during the season: 37% (95% CI -3% - 62%) in the weeks preceding the epidemic peak, -9% (95% CI -63% - 27%) during the peak weeks and -41% (95% CI -109% - 5%) in the post-peak weeks. The overall VE against subtype A(H1N1)pdm09 was 39% (95% CI 11% - 58%) and remained stable during the season. The overall VE against subtype A(H3N2) was -43% (95% CI -89% - -9%), and showed a decreasing trend from values of 26% (95% CI -45% - 62%) at the beginning of the season (pre-peak), to -75% (95% CI - 168 - -15%) in the weeks following the peak period ([Figure 3](#F3){ref-type="fig"}).
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Molecular and phylogenetic analyses carried out on the HA (Haemagglutinin) gene of A(H3N2) strains ([@ref35]) circulating in Emilia-Romagna, identified at the beginning of the season, have shown that A(H3N2) viruses were mainly grouped in subclade 3C.2a1b (vaccine reference strain: A/Singapore/INFIMH-16-0019/2016) and, in a small proportion, in subclade 3C.2a2; however, in the following weeks, A(H3N2) viruses belonging to clade 3C.3a started to circulate more widely. Viruses belonging to subclade 3C.3a are defined by the aminoacid substitutions S91N, N144K, F193S and K326R in HA1. Molecular and phylogenetic analyses carried out on the HA gene of A(H1N1)pdm09 strains ([@ref35]), from January onwards, have shown that they belong to subclade 6B.1A, defined, in HA1, by three additional aminoacid substitutions, S74R, S164T and I295V, compared to the vaccine strain A/Michigan/45/2015. Most of the A(H1N1)pdm09 strains analyzed, present further substitution, S183P, as the new vaccine strain selected for the 2019/2020 season, A/Brisbane/02/2019.

Conclusions {#sec1-4}
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The 2018-2019 influenza season was particularly intense, with a high number of ILI cases and specimens collected, lower only than the 2009-2010 pandemic season. After 2 seasons in which the epidemic peak was anticipated by about 4 weeks, the trend of the epidemic returned to the usual timing, with a peak around the 6^th^ week of surveillance; during this week there was the highest number of swabs performed and viral isolations. In Emilia-Romagna Region A(H1N1)pdm09 and A(H3N2) have co-circulated, with a greater prevalence of the A(H3N2) (57.4% vs 41.2%); the highest number of throat swabs was performed in people over 65 years, most of whom were hospitalized patients with influenza-like symptoms; however, the highest percentage of viral isolation concerned pediatric age groups. The first influenza viruses were identified in hospitalized patients and, only several weeks later, they also appeared in outpatients.

This study has some limitations: although the TN design controls for health care seeking behaviour bias, the VE estimates may not be generalizable to entire population ([@ref22]). We adjusted the VE estimates for age, sex and epidemic season period. However, for a more correct estimate of the VE, it will be necessary to consider, in the future, also a severity score, based on the clinical symptomatology of the disease for each patient.

Our results, although referring to only one Region, suggest that the 2018/19 seasonal vaccine conferred a moderate protection against influenza viruses. The overall seasonal influenza VE was very moderate and showed a rapid decrease from the start of the season, throughout the peak period, until the end of the season.

A good VE against A(H1N1)pdm09 with stable trend in the 3 different periods of the season and a lack of protection against A(H3N2), due to antigenic and genetic mismatch between circulating A(H3N2) and the respective 2018/19 vaccine strain, were observed.

These results reflect what has been observed at national level and in most European Countries, and confirm a wide circulation of A(H3N2) variants antigenically distinct from the vaccine virus A/Singapore/INFIMH-16-0019/2016 ([@ref36]). Phylogenetic analyses carried out in our Laboratory and at the NIC of the ISS, relating to the HA gene of a selection of viruses of subtype A(H3N2) isolated in Parma, have shown how, while in the first part of the season have circulated strains similar to the vaccine, with a moderate value of VE (26%), in the middle weeks of the season began to circulate in Parma, as well as Italy and in other parts of the world ([@ref35], [@ref36]), strains belonging to different genetic subgroups, and in particular to the subclade 3C.3a (reference strain: A/Kansas/14/2017) recently indicated by the WHO as an A(H3N2) component for the 2019/2020 influenza vaccine in the Northern Hemisphere.

In Italy, since the start of this influenza season, 8,104.000 cases of influenza syndrome have been reported; 809 severe cases of confirmed influenza have been reported in subjects with SARI (Severe Acute Respiratory Infection) and/or ARDS (Acute Respiratory Distress Syndrome) admitted to Intensive Care Units; among these, 198 died. In Emilia-Romagna Region, 72 severe cases of confirmed influenza and 53 deaths were reported ([@ref37]).

The contribution given by Virological and Epidemiological Surveillance Programmes allows the correct identification of any variations (minor and major) in the circulating strains and, therefore, the preparation of more targeted vaccines, the effectiveness of which derives from the correct alignment between circulating viruses and antigens contained in the vaccine. The viruses characterization complemented with other available epidemiological and disease information, form the evidence base for Public Health decisions on epidemic response and pandemic preparedness, including seasonal vaccine virus selection and zoonotic influenza candidate vaccine virus development ([@ref38]). Moreover, the timely identification of sick people and their contacts could contain the epidemic, at local level, and direct GPs and P towards more targeted therapies, reducing the risk of evolution in complicated cases, hospitalizations and deaths; in closed communities, and in inpatients it could reduce the risk of infections related to care (Healthcare Associated Infection), especially in subjects at risk for age or chronic disease.

The possibility to make accurate and continuous effectiveness estimates during the season, thanks to the availability of an acquired methodology based on the integration of virological and epidemiological data, combined with sensitive and standardized molecular biology methods, will help to better define the composition of the vaccine for the following season.
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